Orion OYJ (ORINY) vs. Its Rivals Head-To-Head Review

Orion OYJ (OTCMKTS:ORINY) is one of 896 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare Orion OYJ to similar businesses based on the strength of its valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and earnings.

Profitability

This table compares Orion OYJ and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Orion OYJ	30.25%	54.09%	33.33%
Orion OYJ Competitors	-2,381.34%	-218.59%	-15.77%

Analyst Recommendations

This is a summary of recent ratings for Orion OYJ and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orion OYJ	0	1	0	1	3.00
Orion OYJ Competitors	7798	13891	25790	1038	2.41

As a group, “Pharmaceuticals” companies have a potential upside of 24.66%. Given Orion OYJ’s competitors higher probable upside, analysts plainly believe Orion OYJ has less favorable growth aspects than its competitors.

Risk and Volatility

Orion OYJ has a beta of 0.05, suggesting that its share price is 95% less volatile than the S&P 500. Comparatively, Orion OYJ’s competitors have a beta of -3.79, suggesting that their average share price is 479% less volatile than the S&P 500.

Earnings & Valuation

This table compares Orion OYJ and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Orion OYJ	$2.14 billion	$566.04 million	21.42
Orion OYJ Competitors	$3.53 billion	$3.15 billion	552.59

Orion OYJ’s competitors have higher revenue and earnings than Orion OYJ. Orion OYJ is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Dividends

Orion OYJ pays an annual dividend of $0.36 per share and has a dividend yield of 0.6%. Orion OYJ pays out 13.3% of its earnings in the form of a dividend. As a group, “Pharmaceuticals” companies pay a dividend yield of 3.3% and pay out 48.0% of their earnings in the form of a dividend.

Insider & Institutional Ownership

32.6% of shares of all “Pharmaceuticals” companies are held by institutional investors. 14.2% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Orion OYJ competitors beat Orion OYJ on 8 of the 15 factors compared.

About Orion OYJ

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. Further, the company has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal’s generic products. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.